Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 7/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428821 | 1.00 | IRAK1 (0.36) | IRAK1IRAK4METMAPK1GRM2 | |
| SCHEMBL31428920 | 0.94 | GRM2 (0.38) | GRM2 | |
| SCHEMBL31428746 | 0.91 | GRM2 (0.35) | GRM2 | |
| SCHEMBL24975804 | 0.91 | GRM2 (0.35) | GRM2 | |
| SCHEMBL31428539 | 0.91 | GRM2 (0.35) | METGRM2BRD4CREBBP | |
| SCHEMBL31429076 | 0.91 | IRAK1 (0.38) | IRAK1IRAK4METMAPK1GRM2 | |
| SCHEMBL31428465 | 0.87 | GRM2 (0.39) | GRM2 | |
| SCHEMBL24976105 | 0.86 | CREBBP (0.33) | IRAK1IRAK4METMAPK1BRD4 | |
| SCHEMBL31428533 | 0.86 | CREBBP (0.33) | IRAK1IRAK4METMAPK1BRD4 | |
| SCHEMBL24975808 | 0.85 | SLC6A2 (0.39) | GRM2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023008577-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | 国立大学法人神戸大学 | 2023-02-02 | — | — | WO | disclosed |